Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.
2.

Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.

Di Lorenzo G, Ferro M, Buonerba C.

BJU Int. 2012 Jul;110(2 Pt 2):E99-104. doi: 10.1111/j.1464-410X.2011.10790.x. Epub 2011 Dec 16. Review.

3.

Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.

[No authors listed]

Drugs R D. 2006;7(3):197-201. Review.

PMID:
16752945
4.

Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.

Sims RB.

Vaccine. 2012 Jun 19;30(29):4394-7. doi: 10.1016/j.vaccine.2011.11.058. Epub 2011 Nov 26. Review.

5.

Sipuleucel-T (APC8015) for prostate cancer.

So-Rosillo R, Small EJ.

Expert Rev Anticancer Ther. 2006 Sep;6(9):1163-7. Review.

PMID:
17020451
6.

Prostate cancer vaccines: current status and future potential.

Doehn C, Böhmer T, Kausch I, Sommerauer M, Jocham D.

BioDrugs. 2008;22(2):71-84. Review.

PMID:
18345705
7.

Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer.

Thara E, Dorff TB, Pinski JK, Quinn DI.

Maturitas. 2011 Aug;69(4):296-303. doi: 10.1016/j.maturitas.2011.04.012. Epub 2011 May 31. Review.

PMID:
21621934
8.

Provenge: revolutionary technology or ethical bust?

Dickerson JB.

Hum Vaccin. 2011 Apr;7(4):477-80. Epub 2011 Apr 1. Review.

PMID:
21451262
9.

Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer.

Patel PH, Kockler DR.

Ann Pharmacother. 2008 Jan;42(1):91-8. Epub 2007 Dec 19. Review.

PMID:
18094343
10.

Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era.

Arlen PM, Wood LV.

Expert Rev Vaccines. 2012 Mar;11(3):287-302. doi: 10.1586/erv.11.183. Review.

PMID:
22380822
11.

Sipuleucel-T for prostate cancer: the immunotherapy era has commenced.

Buonerba C, Ferro M, Di Lorenzo G.

Expert Rev Anticancer Ther. 2011 Jan;11(1):25-8. doi: 10.1586/era.10.180. Review.

PMID:
21166508
12.

The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature.

Sonpavde G, Di Lorenzo G, Higano CS, Kantoff PW, Madan R, Shore ND.

Eur Urol. 2012 Apr;61(4):639-47. doi: 10.1016/j.eururo.2011.10.027. Epub 2011 Oct 24. Review.

PMID:
22036643
13.

Advances in prostate cancer immunotherapies.

Basler M, Groettrup M.

Drugs Aging. 2007;24(3):197-221. Review.

PMID:
17362049
14.

[Metastatic hormone refractory prostate cancer: new treatment horizon].

Keizman D, Maimon N, Gottfried M.

Harefuah. 2012 Sep;151(9):545-9, 555, 554. Review. Hebrew.

PMID:
23367751
15.

Sipuleucel-T: in metastatic castration-resistant prostate cancer.

Plosker GL.

Drugs. 2011 Jan 1;71(1):101-8. doi: 10.2165/11206840-000000000-00000. Review.

PMID:
21175243
16.

Current vaccination strategies for prostate cancer.

Joniau S, Abrahamsson PA, Bellmunt J, Figdor C, Hamdy F, Verhagen P, Vogelzang NJ, Wirth M, Van Poppel H, Osanto S.

Eur Urol. 2012 Feb;61(2):290-306. doi: 10.1016/j.eururo.2011.09.020. Epub 2011 Oct 3. Review.

PMID:
22001436
17.

Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge).

Harzstark AL, Small EJ.

Expert Opin Biol Ther. 2007 Aug;7(8):1275-80. Review.

PMID:
17696825
18.

Chemotherapy and immunotherapy combination in advanced prostate cancer.

Slovin S.

Clin Adv Hematol Oncol. 2012 Feb;10(2):90-100. Review.

PMID:
22402350
19.

Adjuvants for cancer vaccines.

Dubensky TW Jr, Reed SG.

Semin Immunol. 2010 Jun;22(3):155-61. doi: 10.1016/j.smim.2010.04.007. Epub 2010 May 21. Review.

PMID:
20488726
20.

Development of novel immune interventions for prostate cancer.

Agarwal N, Padmanabh S, Vogelzang NJ.

Clin Genitourin Cancer. 2012 Jun;10(2):84-92. doi: 10.1016/j.clgc.2012.01.012. Epub 2012 Mar 10. Review.

PMID:
22409862
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk